secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001935979-24-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000
--------------------------------------------------------------------------------

- Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.
- R&D expense $314.8M includes $171.9M non-cash milestone/royalty buyback to Knopp for Kv7 platform.
- MoDE platform: Phase 1 BHV-1300 showed dose-dependent IgG reduction, no SAEs; SC formulation had 44% higher exposure vs IV.
- BHV-8000 (TYK2/JAK1) Phase 1 completed; FDA feedback enables registrational programs for Parkinson's and prevention of ARIA.
- Taldefgrobep alfa: Phase 2 obesity trial and Phase 3 SMA topline data expected in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000063/0001935979-24-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000063/bhvn-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001935979-24-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer